Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 34:2023-2030
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andrews, N. P.
Right arrow Articles by Prystowsky, E. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrews, N. P.
Right arrow Articles by Prystowsky, E. N.

CLINICAL STUDIES

Implantable defibrillator event rates in patients with unexplained syncope and inducible sustained ventricular tachyarrhythmias

A comparison with patients known to have sustained ventricular tachycardia

Neil P. Andrews, BMBS, MRCPa, Richard I. Fogel, MD, FACCa, Gemma Pelargonio, MDa, Joseph J. Evans, MD, FACCa and Eric N. Prystowsky, MD, FACCa

a Electrophysiology Section, The Care Group, LLC, Indianapolis, Indiana, USA

Manuscript received June 16, 1998; revised manuscript received July 1, 1999, accepted August 30, 1999.

Reprint requests and correspondence: Dr. Eric N. Prystowsky, The Care Group, LLC, 8333 Naab Rd, Indianapolis, Indiana 46260

OBJECTIVES

To assess the clinical significance of inducible ventricular tachyarrhythmias among patients with unexplained syncope.

BACKGROUND

Induction of sustained ventricular arrhythmias at electrophysiology study in patients with unexplained syncope and structural heart disease is usually assigned diagnostic significance. However, the true frequency of subsequent spontaneous ventricular tachyarrhythmias in the absence of antiarrhythmic medications is unknown.

METHODS

In a retrospective case-control study, the incidence of implantable cardiac defibrillator (ICD) therapies for sustained ventricular arrhythmias among patients with unexplained syncope or near syncope (syncope group, n = 22) was compared with that of a control group of patients (n = 32) with clinically documented sustained ventricular tachycardia (VT). Sustained ventricular arrhythmias were inducible in both groups and neither group received antiarrhythmic medications. All ICDs had stored electrograms or RR intervals. Clinical variables were similar between groups except that congestive cardiac failure was more common in the syncope group.

RESULTS

Kaplan-Meier analysis of the time to first appropriate ICD therapy for syncope and control groups produced overlapping curves (p = 0.9), with 57 ± 11% and 50 ± 9%, respectively, receiving ICD therapy by one year. In both groups, the induced arrhythmia was significantly faster than spontaneous arrhythmias, but the cycle lengths of induced and spontaneous arrhythmias were positively correlated (R = 0.6, p < 0.0001). During follow-up, three cardiac transplantations and seven deaths occurred in the syncope group, and two transplantations and five deaths occurred in the control group (36-month survival without transplant 52 ± 11% and 83 ± 7%, respectively, p = 0.03).

CONCLUSIONS

In patients with unexplained syncope, structural heart disease and inducible sustained ventricular arrhythmias, spontaneous sustained ventricular arrhythmias occur commonly and at a similar rate to patients with documented sustained VT. Thus, electrophysiologic testing in unexplained syncope can identify those at risk of potentially life-threatening tachyarrhythmias, and aggressive treatment of these patients is warranted.

Abbreviations and Acronyms
  CL = cycle length of tachyarrhythmia
  EPS = electrophysiology study
  HV = His to ventricular conduction time
  ICD = implantable cardiac defibrillator
  RR = interval between succeeding QRS complexes
  VT = ventricular tachycardia




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
B. Olshansky, J. E. Poole, G. Johnson, J. Anderson, A. S. Hellkamp, D. Packer, D. B. Mark, K. L. Lee, G. H. Bardy, and for the SCD-HeFT Investigators
Syncope Predicts the Outcome of Cardiomyopathy Patients: Analysis of the SCD-HeFT Study
J. Am. Coll. Cardiol., April 1, 2008; 51(13): 1277 - 1282.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]


Home page
EuropaceHome page
F. Lombardi, E. Calosso, G. Mascioli, E. Marangoni, A. Donato, S. Rossi, M. Pala, F. Foti, and M. Lunati
Utility of implantable loop recorder (Reveal PlusŪ) in the diagnosis of unexplained syncope
Europace, January 1, 2005; 7(1): 19 - 24.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. Brembilla-Perrot, C. Suty-Selton, D. Beurrier, P. Houriez, M. Nippert, A. Terrier de la Chaise, P. Louis, O. Claudon, M. Andronache, A. Abdelaah, et al.
Differences in mechanisms and outcomes of syncope in patients with coronary disease or idiopathic left ventricular dysfunction as assessed by electrophysiologic testing
J. Am. Coll. Cardiol., August 4, 2004; 44(3): 594 - 601.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology
Europace, January 1, 2004; 6(6): 467 - 537.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. D. Krahn, G. J. Klein, R. Yee, J. S. Hoch, and A. C. Skanes
Cost implications of testing strategy in patients with syncope: Randomized assessment of syncope trial
J. Am. Coll. Cardiol., August 6, 2003; 42(3): 495 - 501.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Y. Reddy, P. Neuzil, M. Taborsky, and J. N. Ruskin
Short-term results of substrate mapping and radiofrequency ablation of ischemic ventricular tachycardia using a saline-irrigated catheter
J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2228 - 2236.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
T. Pezawas, G. Stix, J. Kastner, M. Wolzt, C. Mayer, D. Moertl, and H. Schmidinger
Unexplained syncope in patients with structural heart disease and no documented ventricular arrhythmias: value of electrophysiologically guided implantablecardioverter defibrillator therapy
Europace, January 1, 2003; 5(3): 305 - 312.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Menozzi, M. Brignole, R. Garcia-Civera, A. Moya, G. Botto, L. Tercedor, R. Migliorini, X. Navarro, and on behalf of the International Study on Syncope of
Mechanism of Syncope in Patients With Heart Disease and Negative Electrophysiologic Test
Circulation, June 11, 2002; 105(23): 2741 - 2745.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. Garcia-Moran, L. Mont, A. Cuesta, M. Matas, and J. Brugada
Low recurrence of syncope in patients with inducible sustained ventricular tachyarrhythmias treated with an implantable cardioverter-defibrillator
Eur. Heart J., June 1, 2002; 23(11): 901 - 907.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
L. A. Pires, J. R. Ganji, R. Jarandila, and R. Steele
Diagnostic Patterns and Temporal Trends in the Evaluation of Adult Patients Hospitalized With Syncope
Arch Intern Med, August 13, 2001; 161(15): 1889 - 1895.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Mittal, S. C. Hao, S. Iwai, K. M. Stein, S. M. Markowitz, D. J. Slotwiner, and B. B. Lerman
Significance of inducible ventricular fibrillation in patients with coronary artery disease and unexplained syncope
J. Am. Coll. Cardiol., August 1, 2001; 38(2): 371 - 376.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al.
Guidelines on management (diagnosis and treatment) of syncope
Eur. Heart J., August 1, 2001; 22(15): 1256 - 1306.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement